IP Guides

Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting of patent claims for biological products. Understanding how to incorporate these parameters into an IP protection strategy is now essential. Why is this issue becoming more prevalent? The number of cases related to antibodies and quality attributes is increasing for...

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade mark registrations which came about as a result of the Brexit transition, this date marks the end of the period by which the use of the trade mark in the EU prior to the end of the Brexit transitional period is of relevance in the defence of UK non-use revocation actions. This cut off date also impacts EU trade mark registrati...